Open Government Portal

The purpose of this Notice of Amendment is to notify about the additions of Dequalinium chloride, Enfortumab vedotin, Somatrogon, and Tralokinumab to the Prescription Drug List (PDL) for human and veterinary use.

The purpose of this Notice of Amendment is to notify about the additions of gemtuzumab ozogamacin, gilteritinib, icosapent ethyl, tafamidis, trifarotine and upadacitinib to the Prescription Drug List (PDL) for human and/or veterinary use.

The purpose of this Notice of Amendment is to notify about the additions of Alpelisib, Baloxavir marboxil, Betula verrucosa (white birch), Brolucizumab, Cabotegravir, Caplacizumab, Ciclesonide, Darolutamide, Entrectinib, Fremanezumab, Glasdegib, Isatuximab, Siponimod, Tenapanor, Tetracosactide and Tucatinib to the Prescription Drug List (PDL) for human and/or veterinary use.

The Grasslands National Park assesses the riparian health at 31 sample sites along the Frenchman River and Rock Creek watersheds. The overall measure is based on thirteen metrics that are scored subjectively in a semi-quantitative rapid assessment where percent cover is estimated.

This dataset provides statistics on download counts, visitors, as well as the increase of participation of Government of Canada departments and agencies in supplying more open datasets. All statistics presented, unless otherwise noted, are as of June 18, 2013 to the end of the previous month.

Data from surveillance reports provide information on opioid- and stimulant-related harms (deaths, hospitalizations, and responses by emergency medical services) in Canada.

The Public Health Agency of Canada (PHAC) works closely with the provinces and territories to collect and share accurate information about the overdose crisis in order to provide a national picture of the public health impact of opioids and other drugs in Canada and to help guide efforts to reduce substance-related harms.

The Privacy Act (Revised Statutes of Canada, Chapter P-21, 1985) was proclaimed on July 1, 1983.

The Privacy Act provides Canadian citizens and permanent residents with the right of access to, and correction of, personal information about themselves that is under the control of a government institution. The Act also provides the legal framework for the collection, retention, use, disclosure, disposition and accuracy of personal information in the administration of programs and activities by government institutions subject to the Act.

Section 72 of the Privacy Act requires that the head of every government institution prepare for submission to Parliament an …

AAFC has been conducting the Strategic Issues Survey, a survey of producers, since 2007. The research is designed to provide insight into the views of producers on current agricultural issues in Canada and on priorities and policies that affect the agriculture and agri-food sector. The survey builds on tracking questions from previous waves to note trends over time but also provides insights on new and evolving areas of interest to AAFC. This wave of research includes a focus on sustainability, along with other upcoming priorities. This year’s research also continues to track benchmarks of the department’s multi-year agricultural policy framework, …

The primary purpose of the authority codes is to identify expenditure transactions for accountability and reporting in the Public Accounts of Canada according to the specific votes and other authorities in the Estimates, other authorities included in specific statutes; and in addition, to identify the nature of revenue, by tax and non-tax revenue. Other authority codes (non-appropriated authorities) are also established by central agencies to facilitate the identification of various accounting transactions that do not require the use of appropriations. An appropriation is an authority of Parliament to pay money out of the Consolidated Revenue Fund (CRF) and as such, …

This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to Section C.08.004 of the Food and Drug Regulations. In the absence of a guidance specific to Quality changes to drugs which were approved through a Drug Identification Application - Biologics (DIN-B drugs), this guidance document applies to those products. This guidance also applies to those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold.